About DLHAX
Macquarie Healthcare Fund Class A is a mutual fund designed to pursue long-term capital growth by investing principally in companies within the healthcare sector. The fund’s portfolio focuses on equity securities of firms engaged in the development, production, or distribution of medical products and services, spanning segments such as pharmaceuticals, biotechnology, medical devices, and healthcare services. Key holdings typically include prominent industry leaders like Eli Lilly and Co, Amgen Inc, and Regeneron Pharmaceuticals, among others. Managed since 2007, the fund employs a strategy that requires at least 80% of its assets to be concentrated in healthcare-related businesses, making it a sector-specific investment vehicle. This focused approach enables the fund to benefit from innovations and demographic trends in healthcare, but it also exposes investors to industry-specific risks, including regulatory changes and evolving medical technologies. With a minimum investment requirement and annual dividend distributions, Macquarie Healthcare Fund Class A serves as a targeted option for those seeking exposure to the healthcare market within a diversified investment portfolio.
Fund Family Nomura
Category Health
Performance Rating High
Risk Rating Below Average
Stock Exchange Nasdaq
Ticker Symbol DLHAX
Share Class Class A
Index Russell 3000 Healthcare TR
DLHAX had a total return of 13.93% in the past year, including dividends. Since the fund's
inception, the average annual return has been 13.50%.
